MAPT and Parkinson disease: Because tau reduction effectively prevented AD-like abnormalities in hAPP transgenic mice but not PD-like deficits in the models analyzed here, it is tempting to speculate that tau plays different roles also in the human conditions and that tau reduction might be beneficial in AD, but not in the most common forms of PD.